James L. Slack - Concepedia

Author

James L. Slack

Roswell Park Comprehensive Cancer Center

Also Known As

J L Slack, J Slack, J. L. Slack, J. Slack, J.L. Slack, JAMES L. SLACK, James L Slack, James L. Slack, James Slack, Robert J. Soiffer

149

Publications

6.5K

Citations

H-Index

Concepts

All Affiliations

Roswell Park Comprehensive Cancer Center Mayo Clinic in Florida Mayo Clinic Hospital Mayo Clinic in Arizona WinnMed

About

James L. Slack is an author at Roswell Park Comprehensive Cancer Center specializing in medicine, hematology, and transplantation.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	22	1.1K
2	Health Sciences	6	6	230
3	Engineering	2	2	218
4	Public Health	2	2	145
5	Natural Sciences	1	1	52

James L. Slack

Publications

5.8K

Citations

H-Index

Page 1

	Year	Citations
Decitabine improves patient outcomes in myelodysplastic syndromes Hagop M. Kantarjian, Jean‐Pierre J. Issa, C Rosenfeld, Cancer	2006	1.5K
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML Courtney D. DiNardo, Eytan M. Stein, Stéphane de Botton, New England Journal of Medicine	2018	1.4K
Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial David P. Steensma, Maria R. Baer, James L. Slack, Journal of Clinical Oncology	2009	313
Advances in second generation high temperature superconducting wire manufacturing and R&D at American Superconductor Corporation M.W. Rupich, Xiaoping Li, Cees Thieme, Superconductor Science and Technology Superconducting MaterialEngineeringThicker Ybco LayersCoated ConductorsAdvanced Packaging (Semiconductors)	2009	166
Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502 Steven M. Devine, Kouros Owzar, William Blum, Journal of Clinical Oncology	2015	158
Financial Burden in Recipients of Allogeneic Hematopoietic Cell Transplantation Nandita Khera, Yu‐Hui Chang, Shahrukh K. Hashmi, Biology of Blood and Marrow Transplantation Treatment NonadherenceFinancial BurdenTransplantationHealthcare ValueHealth Policy	2014	127
Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML) P. Wijermans, Björn Rüter, Maria R. Baer, Leukemia Research Hematological MalignancyOncologyChronic Myelomonocytic LeukemiaMedicineMixed-phenotype Acute Leukemia	2007	124
Association of PML-RAR alpha fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study. Robert E. Gallagher, Cheryl L. Willman, James L. Slack, PubMed	1997	122
Secondary cytogenetic changes in acute promyelocytic leukemia--prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: a Cancer and Leukemia Group B study. James L. Slack, DC Arthur, David Lawrence, Journal of Clinical Oncology	1997	120
A phase 2 study of vorinostat in acute myeloid leukemia Élise Schaefer, Arturo Loaiza‐Bonilla, Mark Juckett, Haematologica	2009	117

Page 1